Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

MAZE

NASDAQ

Maze Therapeutics (MAZE)

31.40 USD −3.18% vs prior close Nov 20, 2026
Maze Therapeutics, Inc. price graph
64 sessions
40 20 24 Aug 20 Nov

The line runs 30 USD on 24 August through 31.40 USD on 20 November, on a scale from 20 to 40. Days the market did not trade hold the previous close, flat.

Market cap
1.7B USD
EPS, diluted, year to Dec 2025
−3.05 USD
52-week range
22 USD – 52 USD
Avg volume
59.7K
Mentions, 30 days
5
Net sentiment
+0.01

as of Nov 20, 2026

Have Maze Therapeutics (MAZE) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Maze Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Jan 2026, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 2 Nov 2026

0buys
17sells
$5.79Mnet sold
8other filings
Have Maze Therapeutics (MAZE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
02 Nov 2026Coloma Jason VChief Executive OfficerSell34,5011.0M USD
29 Oct 2026Dandekar AtulCSBOSell7,500241K USD
01 Oct 2026Bernstein HaroldPresident, R&D & CMOSell16,141435K USD
01 Oct 2026Coloma Jason VChief Executive OfficerSell34,501932K USD
29 Sep 2026Dandekar AtulCSBOSell7,500203K USD
04 Sep 2026Bernstein HaroldPresident, R&D & CMOSell9,705255K USD
03 Sep 2026Bernstein HaroldPresident, R&D & CMOSell5,189135K USD
03 Sep 2026Coloma Jason VChief Executive OfficerSell11,411297K USD
03 Sep 2026Courtney PhillipsGC and Corp. SecretarySell2,01252K USD
03 Sep 2026Dandekar AtulCSBOSell3,24384K USD
02 Sep 2026Bernstein HaroldPresident, R&D & CMOSell5,106135K USD
02 Sep 2026Coloma Jason VChief Executive OfficerSell11,227297K USD
Sold17 open-market sales211,350$5.79M

Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.

8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Maze Therapeutics (MAZE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
29 Oct 2026Dandekar AtulCSBOOption exercise7,50078K USD
01 Oct 2026Bernstein HaroldPresident, R&D & CMOOption exercise16,141168K USD
29 Sep 2026Dandekar AtulCSBOOption exercise7,50078K USD
01 Sep 2026Bernstein HaroldPresident, R&D & CMOOption exercise36,141168K USD
01 Sep 2026Coloma Jason VChief Executive OfficerOption exercise50,000
01 Sep 2026Courtney PhillipsGC and Corp. SecretaryOption exercise11,000
01 Sep 2026Dandekar AtulCSBOOption exercise12,500
28 Aug 2026Dandekar AtulCSBOOption exercise7,50078K USD

Which funds hold Maze Therapeutics (MAZE)?

4 of the 45 institutional funds we track reported a Maze Therapeutics position for the quarter ended 30 Sep 2026 — a combined 79.6M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Maze Therapeutics (MAZE)?
FundPositionSharesValueShares q/q
Citadel AdvisorsAdded1,579,81842.9M USD+85.3%
Marshall WaceAdded1,166,10831.7M USD+27.5%
Two Sigma InvestmentsHeld (±25%)154,3834.2M USD−20.0%
AQR Capital ManagementHeld (±25%)26,983733K USD−0.7%
Balyasny Asset ManagementExited
D. E. Shaw & Co.Exited

What has been filed or recorded for Maze Therapeutics (MAZE)?

The filings we hold for Maze Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Maze Therapeutics (MAZE)?
And
30 Oct 2026Fails to deliverShares failed to deliver27,000 shares862K USD notional · 0.049% of shares out
19 Oct 2026Fails to deliverShares failed to deliver19,693 shares542K USD notional · 0.036% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.79 USDRevenue $20M
30 Sep 2026FinancialsTotal assets511.6M USDat period end
30 Sep 2026FinancialsTotal equity428.5M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.76 USDRevenue $20M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.45 USDRevenue $20M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.05 USD
31 Dec 2025FinancialsNet income−131.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.05 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.66 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.77 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.15 USD
31 Dec 2024Annual reportFY 2025 reportedEPS 1.25 USDRevenue $168M

What is Reddit saying about Maze Therapeutics (MAZE)?

Reddit mentioned MAZE 5 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 60% read bullish, 40% bearish and 0% neither. Reddit data updated 21 November 2026.

30-day window, Method

5mentions, 30 days
60%bullish
40%bearish
1communities
+8pointsagainst the market

How do Reddit mentions of Maze Therapeutics (MAZE) compare with its price?

Share ↗
5 mentions

Which subreddits are talking about Maze Therapeutics (MAZE)?

30 days

Which subreddits are talking about Maze Therapeutics (MAZE)?
CommunityShareMentionsNet sentiment
r/wallstreetbets100%5+0.01

What do people ask about Maze Therapeutics (MAZE)?

From live data
What did Maze Therapeutics shares close at?31.40

Maze Therapeutics closed at 31.40 USD on 20 Nov 2026, down 3.18% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Maze Therapeutics’ market cap?1.7B

Maze Therapeutics is worth 1.7B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Maze Therapeutics insiders bought or sold shares recently?17 sales

In the 90 days to 22 Nov 2026, Maze Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Jan 2026, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Maze Therapeutics?4 of 45

4 of the 45 funds we track reported a Maze Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Marshall Wace and Two Sigma Investments. See Funds

When did Maze Therapeutics last report earnings?−0.79

Maze Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.79 USD; no next date is announced in SEC filings yet. See Filings

What is Reddit saying about Maze Therapeutics?0 mentions

Maze Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 5 times over the trailing 30 days. Of the 5 mentions scored for sentiment, 60% read bullish and 40% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARForm 4 filings (insider transactions)
  5. SEC EDGAR13F filings
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings
  10. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words